Echocardiographic evidence for valvular toxicity of Benfluorex: A double-blind randomised trial in patients with type 2 diabetes Mellitus

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Derumeaux, Geneviève ^a   Ernande, Laura ^a   Serusclat, André ^a   Servan, Evelyne ^a   Bruckert, Eric ^b   Rousset, Hugues ^c   Senn, Stephen ^d   van Gaal, Luc ^e   Picandet, Brigitte ^f   Gavini, François ^f   Moulin, Philippe ^g  

^a LOUIS PRADEL HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CENTRE HOSPITALIER   (France)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^g UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENFLUOREX; HEMOGLOBIN A1C; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

ADULT; ANEMIA; AORTA VALVE DISEASE; AORTA VALVE REGURGITATION; AORTA VALVE STENOSIS; ARTICLE; ASTHENIA; BENIGN TUMOR; BLOOD TOXICITY; CARDIOTOXICITY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CYST; DIABETIC PATIENT; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FALLING; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HEART VALVE REGURGITATION; HUMAN; HYPOGLYCEMIA; INFECTION; INFESTATION; INJECTION SITE EDEMA; LUNG TOXICITY; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MITRAL VALVE DISEASE; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; PARALLEL DESIGN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; POLYP; PREGNANCY DISORDER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THORAX DISEASE; TREATMENT FAILURE; TRICUSPID VALVE DISEASE; TRICUSPID VALVE REGURGITATION; TRICUSPID VALVE STENOSIS; VALVULAR HEART DISEASE; WEIGHT GAIN;

AGED; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; FEMALE; FENFLURAMINE; HEART VALVE DISEASES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84862534255     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038273     Document Type: Article

References (29)

1. Moulin P, Andre M, Alawi H, dos Santos LC, Khalid AK, et al. (2006) Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18-week, randomized, double-blind study. Diabetes Care 2006 29: 515-520.
2. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, et al. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003 108: 2941-2948.
3. Rafel RJ, Casañas MR, Anguera FN, Batalla SN, Castro CA, et al. (2003) [Valvular heart disease associated with benfluorex]. Rev Esp Cardiol 2003 56: 215-216.
4. Noize P, Sauer M, Bruneval P, Moreau M, Pathak A, et al. (2006) Valvular heart disease in a patient taking benfluorex. Fundam Clin Pharmacol 2006 20: 577-578.
5. Thevis M, Sigmund G, Gougoulidis V, Beuck S, Schlörer N, et al. (2010) Screening for benfluorex and its major urinary metabolites in routine doping controls. Anal Bioanal Chem 2010; In press.
6. Seuwen K, Magnaldo I, Pouysségur J, (1988) Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature 1988 335: 254-256.
7. Boutet K, Frachon I, Jobic Y, Gut-Gobert C, Leroyer C, et al. (2009) Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J 2009 33: 684-688.
8. Frachon I, Etienne Y, Jobic Y, Le Gal G, Humbert M, et al. (2010) Benfluorex and unexplained valvular heart disease: a case-control study. PLoS ONE 2010 5: e10128.
9. Weill A, Païta M, Tuppin P, Fagot J-P, Neumann A, et al. (2010) Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010 19: 1256-1262.
10. AFSSAPS (2009) National Pharmacovigilance Committee meeting of Tuesday 29 September 2009. AFSSAPS 2011.
11. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, et al. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007 356: 39-46.
12. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, et al. (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003 16: 777-802.
13. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT, (1998) An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998 339: 725-732.
14. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, et al. (2004) Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004 363: 1179-83.
15. Dahl CF, Allen MR, Urie PM, Hopkins PN, (2008) Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 2008 6: 34.
16. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, et al. (2000) Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000 101: 2071-2077.
17. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J, (2009) Drug-induced fibrotic valvular heart disease. Lancet 2009 374: 577-585.
18. Roth BL, (2007) Drugs and valvular heart disease. N Engl J Med 2007 356: 6-9.
19. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, et al. (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000 102: 2836-2841.
20. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, et al. (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997 337: 581-588.
21. Gustafsson BI, Tømmerås K, Nordrum I, Loennechen JP, Brunsvik A, et al. (2005) Long-term serotonin administration induces heart valve disease in rats. Circulation 2005 111: 1517-1522.
22. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, et al. (2006) Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 2006 113: 81-89.
23. Rothman RB, Redmon JB, Raatz SK, Kwong CA, Swanson JE, et al. (2000) Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. Am J Cardiol 2000;85: 913-915, A10.
24. Droogmans S, Roosens B, Cosyns B, Degaillier C, Hernot S, et al. (2009) Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study. Am J Physiol Heart Circ Physiol 2009 296: H1940-1948.
25. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, et al. (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000 57: 75-81.
26. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, et al. (2003) 3,4-methylenedioxymethamphetamine (MDMA, « Ecstasy ») induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003 63: 1223-1229.
27. Huang X-P, Setola V, Yadav PN, Allen JA, Rogan SC, et al. (2009) Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol 2009 76: 710-722.
28. Nebigil CG, Maroteaux L, (2003) Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure? Circulation 2003 108: 902-908.
29. Levy RJ, (2006) Serotonin transporter mechanisms and cardiac disease. Circulation 2006 113: 2-4.